Welcome!
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Пуния Викрам Сингх
Vikram Singh Punia
President, Pharmasyntez
Quotes
07.06.2019
SPIEF 2019
Russia–India
It is feesible to talk to the government of India to create a special economic zone for the Russian pharmaceutical industry. India could prepare the infrastructure, tax incentives, and all the prerequisites so that we could invest into the Indian economy. <…> Pharmasyntez alone could invest over USD 100 million in pharmaceutical substances over the next 3–4 years. The same model could be used for Indian companies in Russia
07.06.2019
SPIEF 2019
Russia–India
Unfortunately, our trade [in pharmaceutical sector – Ed.] is stalling. If we take the turnover between India and the US it is over USD 6 billion, while with Russia the number is less than 400 million. <…> We need a new cooperation model between India and Russia
06.06.2019
SPIEF 2019
A Substantive Dialogue Between Global Pharmaceutical Players and BRICS Economies on the Rules of Fair and Equitable Competition
There should absolutely be compulsory licensing in Russia, but under the condition that it only happens in critical situations. This must come under the purview of the Federal Antimonopoly Service, like it does in the US and other civilized nations
25.05.2018
SPIEF 2018
Russia–India
The foreign trade volume between Russia and India is about $10 billion. By 2025 this figure should grow to $35 billion. Now the countries cooperate in nuclear power engineering, defense industry, microelectronics, scientific and technical research and other spheres. Building facilities to produce pharmaceutical substances in Russia may become a profitable area for the Indian investors